9993467

Celgene sued Dr. Reddy's in an ANDA/Hatch-Waxman action concerning pomalidomide (POMALYST®) patents, including U.S. Pat. Nos. 8,198,262; 8,735,428; 8,828,427; and 9,993,467. The narrative states that US3845770 does not appear to have been asserted in this case, despite its association with the patent-page litigation listing. Final judgment was entered on February 23, 2022.

Hatch-Waxman ANDA litigation. Consent judgment entered June 15, 2022 (Judge Esther Salas): permanent injunction; all claims/counterclaims dismissed with prejudice. Patents-in-suit expressly included 8,828,427 plus '262, '939, '428, '467, '5939.

Hatch-Waxman ANDA litigation concerning Sandoz ANDA No. 220741. Consent judgment Nov. 17, 2025: permanent injunction barring Sandoz's ANDA product until expiration of patents-in-suit; § 271(e)(1) and Paragraph IV rights expressly preserved.

Hatch-Waxman ANDA litigation concerning Cipla ANDA No. 219718 (1/2/3/4 mg). Consent judgment entered Sept. 11, 2025; case closed Sept. 17, 2025. Patents-in-suit: 8,828,427; 9,993,467; 10,555,939. Injunction until expiration; no damages.

Hatch-Waxman ANDA litigation filed after Dr. Reddy's ANDA (Mar. 29, 2019) and Paragraph IV notice (May 31, 2019); asserted '262, '3939, '428, '427, and '467. Outcome not confirmed in the sources reviewed.

Lead consolidated case for Celgene's pomalidomide ANDA litigation against Hetero; many earlier generic ANDA cases were consolidated into this case.

Celgene's 2018 ANDA infringement case against an unidentified generic pomalidomide filer; consolidated into lead case 17-cv-3387 by Consolidation Order on 2019-01-31.

Celgene's ANDA infringement suit against Apotex; docket shows civil case terminated on 2019-02-08 upon consolidation into lead case 17-cv-3387.

Celgene's 2025 pomalidomide ANDA infringement suit against USV Private Limited; listed as remaining open.

Federal Circuit appeal of the 2:19-cv-05802 venue dismissal; affirmed on Nov. 5, 2021, holding Mylan lacked a regular and established place of business in New Jersey and that the ANDA submission, not the paragraph IV notice letter, is the operative infringing act.

Antitrust litigation in S.D.N.Y. challenging Celgene's enforcement of pomalidomide patents including the '467; complaints dismissed March 2025, judgment entered for defendants March 2026, and notice of appeal to the Second Circuit filed April 2026.

Antitrust action by The Cigna Group against Celgene Corp. in the Pomalyst antitrust litigation; complaints dismissed March 2025, judgment entered for defendants March 2026, and appeal to the Second Circuit filed April 2026.

Hatch-Waxman ANDA patent-infringement suit involving pomalidomide (ANDA No. 213234). Patents asserted included U.S. 8,198,262, 8,673,939, 8,735,428, 8,828,427, and U.S. 9,993,467. A consent judgment enjoined Dr. Reddy's from infringing the patents-in-suit until expiration and dismissed all claims, counterclaims, and defenses with prejudice.